Abstract
Agents blocking BRAF and MEK produce robust responses in patients with BRAF(V600) -mutated melanoma; however, more accurate clinical biomarkers are needed to predict prognosis. To explore this question, we retrospectively studied 158 patients with BRAF-mutated melanoma treated with BRAF with or without MEK inhibitors. We found that the number of distinct tumor sites upon initiation of targeted therapy was associated with decreased progression-free survival but had no effect on overall survival. Serum values of lactate dehydrogenase and absolute lymphocyte count to absolute neutrophil count ratio independently had the strongest association with both progression-free survival and overall survival. Using both of these markers can help stratify prognosis of patients with metastatic melanoma receiving targeted therapy.